Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chapel Down appoints new CFO

(Sharecast News) - English wine producer Chapel Down has announced the appointment of the former Typhoo Tea and Fevertree Drinks finance leader as its new chief financial officer. Lourens Mouton, who has also held roles at Natural Capital Partners, BHP Billiton and Deloitte, will be appointed as CFO in early April, replacing Rob Smith who announced his resignation from the firm after two years in December.

Smith will step down after finalising and issuing Chapel Down's full-year results, expected next month.

The hire marks the second major boardroom change in just two months, with James Pennefather starting as the company's new chief executive officer last month.

"We are delighted to have appointed Louan, who has an excellent track record of leading cross-functional teams through significant growth and transformation in publicly traded and private international businesses," said chair Martin Glenn in a statement.

"He is a dynamic leader of high-performing finance teams and I am confident that, alongside our new CEO James Pennefather, he will continue the delivery of Chapel Down's development and growth."

Shares were down 0.3% at 39.9p by 1210 GMT, having fallen by 34% over the past six months.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.